# Bisantrene Combination for Resistant AML

> **NCT04989335** · PHASE2 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 29 (estimated)

## Conditions studied

- Myelogenous Leukemia, Acute

## Interventions

- **DRUG:** Bisantrene
- **DRUG:** Fludarabine
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT04989335
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-02
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989335, "Bisantrene Combination for Resistant AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04989335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*